The 50Plus Group and Decima Research Build Leadership in Canada's Largest, Most Affluent Consumer Segment

The 50Plus Group and Decima Research Build Leadership in Canada's Largest, Most Affluent Consumer Segment

Fifty-Plus. net International Inc. (TSX/V:FPN), which owns a portfolio of Internet media operating as The 50Plus Group, and Decima Research, Canada’s fastest-growing full service marketing research company, today announced an exclusive partnership to develop market research insights and services for marketers interested in the largest and most affluent segment of the Canadian consumer marketplace.

Toronto, ON (PRWEB) February 3, 2006

Fifty-Plus. net International Inc. (TSX/V:FPN), which owns a portfolio of Internet media operating as The 50Plus Group, and Decima Research, Canada’s fastest-growing full service marketing research company, today announced an exclusive partnership to develop market research insights and services for marketers interested in the largest and most affluent segment of the Canadian consumer marketplace.

Under the terms of the multi-year agreement:

The 50Plus Group’s entire audience will be invited to join Decima’s market-leading EVOX on-line survey research panel, and complete surveys on a wide variety of subjects, in exchange for rewards of varying types. (In recent months, Decima announced a partnership with Aeroplan, under which one of the incentives available for survey completion is Aeroplan Miles.) This online audience includes visitors to The 50Plus Group’s flagship site, www.50plus. com, as well as the www. carp. ca, the official web site of CARP, Canada’s Association for the Fifty-Plus ( managed by The 50Plus Group), and www. theskillsmatch. ca, the first employment web site in Canada specializing in the 50-plus market, as well as opt-in subscribers to five e-newsletters.

Decima is establishing a 50 Plus Specialty Practice, led by company Partner Dan Kirkland, to direct the development of these syndicated products and offer custom research studies to current and future Decima clients. Mr. Kirkland is one of Canada’s most experienced and successful research executives. Decima will, as a result of this partnership, have the ability to do highly targeted studies in this market in an extremely cost-efficient manner, using on-line, telephone, or focus group methodologies as appropriate.

. Decima and The 50Plus Group will collaborate on the design of a series of syndicated studies of consumer behavior and attitudes in this vital segment. These studies will be targeted in a number of areas, including:

-- lifestyle and lifestyles 

-- home entertainment/electronics

-- investment products and services 

-- automotive

-- insurance products and services 

-- books, music, TV and film

-- travel and leisure 

-- gaming

-- health and fitness 

-- real estate

-- health products and services 

-- government programs

-- pharma and nutraceutical products 

-- philanthropy and volunteerism

-- telecommunications services 

-- information services/Internet use

The 50Plus Group will offer its clients preferred access to Decima Research data and consulting services, and will offer turnkey research and marketing solutions in partnership with Decima.

50Plus Group President Eric Vengroff noted, “Demand for marketing and public affairs insights into the 50-plus segment is exploding, as is demand for marketing solutions. This partnership with one of Canada’s most dynamic and respected research houses puts us in a position to provide unrivalled expertise when it comes to the design and delivery of marketing solutions for leading brands and institutions across the public, private and not-for-profit sectors.”

Decima CEO Bruce Anderson noted, “The future of research lies in building large panels of people who are willing to share information about their values, preferences, and behaviors, being able to reach them in a targeted, time and cost efficient manner, and to develop compelling and practical insights for clients. As a result of this partnership, Decima will enjoy a pioneering position in the Canadian marketplace, when it comes to this most vital consumer segment. We are delighted to be partnering with Canada’s leader in marketing services for the 50-plus segment.”

Decima Partner Dan Kirkland added, “For years our clients have been hoping that tools would be developed that allow for cost effective insights into how consumers evolve after reaching the age of 50. There’s no doubt that they are not and will not simply replicate what previous generations did -- they are awash in information, improved in health, and in many cases, flush with financial resources. We’re inspired to be the company that will learn the most about this phenomenon and offer that learning to our clients.”

For more information:

DECIMA RESEARCH  THE FIFTY PLUS GROUP

Bruce Anderson, CEO  Eric Vengroff, President

(613) 230-2200  (416) 363-8748, ext 237

Dan Kirkland, Partner  David Cravit, Sr. VP, Marketing 

(416) 962-2013  (647) 280-8163

# # #

FDA Advisory Panel Unanimously Recommends Approval of Ortec's Tissue Engineered Prodcut, OrCel for Treatment of Donor Site Wounds in Burn Victims

FDA Advisory Panel Unanimously Recommends Approval of Ortec's Tissue Engineered Prodcut, OrCel for Treatment of Donor Site Wounds in Burn Victims

If approved, OrCel™ will be the second product of this kind to market, after Organogenesis' Apligraf product. Ortec believes OrCel™ has three major advantages over Apligraf. First is distribution, Ortec is the only company in its field with the ability to cryopreserve its products. This will increase Ortec's ability to penetrate the market, reduce overhead and manufacturing costs for the company and competitively compete price wise. Ortec's product is much easier to use, without complicated preparation and application procedures. Thirdly, Ortec's technology demonstrated superior clinical results in reports submitted to the FDA earlier this year.

(PRWEB) July 26, 2001

New York, NY - (BUSINESSWIRE) - July 17th, 2001 - Ortec International, Inc. (NASDAQ: ORTC) announced today that The General and Plastic Surgery Devices Advisory Panel of the U. S. Food and Drug Administration (FDA) unanimously recommended approval of Ortec’s substitute engineered skin, OrCelÔ, for use in treatment of donor site wounds in burn victims. The panel recommended further histology characterizations and label clarifications for specific use with in certain patient populations.

In March of this year, Ortec filed a Pre-Market Approval (PMA) application with the FDA requesting permission to market its product for the treatment of donor site wounds in burn patients. On April 4th, 2001, the FDA notified Ortec that its PMA application was accepted. On May 14th, 2001, the FDA notified Ortec that its product was placed on the agenda for review by the General and Plastic Surgery Devices Panel.

Commenting on the panel's recommendation, Steven Katz, Ph. D. Chairman and CEO said, "This is clearly an achievement of a significant milestone for Ortec. We are obviously pleased by the panel's favorable recommendation and look forward to working with the FDA towards obtaining a final marketing approval and making our product commercially available for this significant medical need."

John Griswald, M. D., F. A.C. S., Peter Canizarrow Professor of Surgery, Medical Director Burn Center, Texas Tech University Health Sciences Center, one of the clinical investigators who participated in the donor site trial, presented to the panel the clinical need for new technologies to treatment donors site wounds and his experience with OrCelÔ. Commenting on his experience Griswald said, OrCelÔ, represents a significant advance in the treatment of donor site wounds in burn patients, and I am looking forward to the FDA approval of OrCelÔ and its availability for use on burn victims.

Over 1.25 million people are treated annually for burns at medical facilities across the U. S. Donor site wounds, a market estimated to be in excess of $1 million, are wounds created where skin is taken from an uninjured part of the body to cover a burned area on another part of the body.

In addition to the donor site indication, Ortec is pursuing the application of its product to other medical indications estimated to be in excess of $1 billion. Ortec recently received FDA approval under a Humanitarian Device Exemption for hand reconstruction and donor sites created in this procedure for victims of Epidermolysis Bullosa. In addition, Ortec is pursuing FDA approvals for venous and diabetic skin ulcers and is in the midst of clinical trials for those indications.

About Ortec International, Inc.

Ortec International, Inc. is a tissue-engineering company involved in the commercialization of a proprietary and patented technology to stimulate the repair and regeneration of human tissue. OrtecÂ’s current focus is the application of its Composite Cultured Skin (CCS) product to heal chronic and acute wounds. Ortec believes that its platform technology may extend to the development of other human tissue, such as tendons, ligaments, cartilage, bone, muscle and blood vessels. Ortec recently received FDA approval under a Humanitarian Device Exemption for hand reconstruction and donor sites created in this procedure for victims of Epidermolysis Bullosa. Ortec is also pursuing FDA approvals for venous and diabetic skin ulcers and is in the midst of clinical trials for those indications.

Certain statements made in this news release that express the belief, potential anticipation or expectation, as well as other statements which are not historical fact, and statements relating to the clinical trials and their results, design, FDA product approvals or other marketing approvals, features, functionality and performance insofar as they may apply prospectively, are "forward looking" statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties. The CompanyÂ’s actual results may differ significantly from the results discussed in this news release or in other "forward looking" statements presented by management. Factors that might cause such a difference include, but are not limited to, development by the CompanyÂ’s competitors of new technologies or products that are more effective than the CompanyÂ’s, risks of failure of clinical trials, dependence on and retention of key personnel, protection of proprietary technology, compliance with U. S. Food and Drug Administration regulations, continued availability of raw material for the CompanyÂ’s products, availability of product liability insurance in the event of commercialization of the CompanyÂ’s products, ability to effect transition from pilot-scale manufacturing to large-scale commercial production of products, uncertainty as to the availability of additional capital on acceptable terms, if at all, and the demand for the CompanyÂ’s products, if and when commercially available.

  FOR MORE INFORMATION, PLEASE CONTACT:

Ron Lipstein, CFO At Ortec International, Inc. (212) 740-6999, ext. 204

Www. ortecinternational. com

ThreeLac - Effective in the fight against Candida

ThreeLac - Effective in the fight against Candida

ThreeLac Candida Treatment is a revolutionary Candida Treatment that originates from Japan where it has been amazingly successful.

(PRWEB) October 24, 2004

ThreeLac Candida Treatment is a revolutionary Candida Treatment that originates from Japan where it has been amazingly successful - in 2001 over $50 million of Threelac was sold which does indicate that it works. The manufacturers are therefore not shy in describing ThreeLac as "the most effective candida treatment product in the marketplace".

Threelac has a proprietary formula that is teeming with live bacteria. These start to work immediately to help rid the body of resilient candida organisms. You can expect results starting from day one!

The secret behind the effectiveness of ThreeLac is the micro-encapsulation process that gets the candida fighting live bacteria safely past the acidic environment in the stomach.

These oxygen-friendly bacteria go to work "dining" on anaerobic problem organisms that your body does not need. An added benefit is that it helps to balance the bodyÂ’s pH. When you use this groundbreaking product to fight candida, there will be no need to adhere to impossible dietary restrictions. For general health reasons, use common sense and avoid processed sweets. Eat your sweets "raw" and enjoy a good diet rich in nutritious foods.

ThreeLac restores the pH levels of the body to a favourable level and this is instrumental in the management of candidiasis. This ultimatly brings relief from typical candida symptoms, which may include depression, anxiety, recurring irritability, heartburn, indigestion, lethargy, extreme food and environmental allergies, acne, dry, flaky, itchy skin, jock itch, migraine headaches, recurring cystitis/vaginal infections, premenstrual tension, and menstrual problems.

You can try this simple test to see if you have candida: First thing in the morning, before you put ANYTHING in your mouth, get a clear glass and fill with water.

Now work up a bit of saliva, then spit it into the glass of water. Check the water every 15 minutes or so for up to one hour. If you have a problem that ThreeLac can help with, you will see strings (like legs) travelling down into the water from the saliva floating on the top, or "cloudy" saliva will sink to the bottom of the glass, or cloudy specks will seem to be suspended in the water. If there are no strings and the saliva is still floating after at least one hour, you probably have candida under control. ThreeLac would then be used to maintain good bowel flora and proper pH.

Tel: 08701 644822

Email: info@bodykind. com

Web: www. bodykind. com

# # #

Kentucky Equality Federation Urges the U. S. Senate to Deny the Confirmation of Dr. James Holsinger as U. S. Surgeon General

Kentucky Equality Federation Urges the U. S. Senate to Deny the Confirmation of Dr. James Holsinger as U. S. Surgeon General

Kentucky Equality Federation condemns the nomination of Kentucky's Dr. James Holsinger as U. S. Surgeon General and urges the U. S. Senate not to confirm him.

Lexington, KY (PRWEB) June 11, 2007

Kentucky Equality Federation today condemned the nomination of Dr. James W. Holsinger Jr. as U. S. Surgeon General.

Federation management had previously decided to remain largely quiet on the issue since the Office of U. S. Surgeon General is not a particularly powerful one, and has little direct impact on policy-making.

Earlier this week however Truth Wins Out, a group that debunks the religious right, reported that Dr. James Holsinger helped found a church in Lexington, Kentucky that operates an "ex-gay" ministry, a practice strongly opposed by Kentucky Equality Federation.

In 2006 the American Psychiatric Association, backed by numerous other mainstream medical organizations, issued a warning which stated: "There is simply no sufficiently scientifically sound evidence that sexual orientation can be changed." The statement went on to say that positions supported by ex-gay organizations "are not supported by the science" and that they "create an environment in which prejudice and discrimination can flourish." The medical and scientific consensus is that reparative therapy is not effective and is potentially harmful.

"After reading some of the information and reports currently being circulated in the gay community it is clear that Dr. Holsinger has homophobic issues and isn't worthy to be a physician, much less U. S. Surgeon General," stated Jordan Palmer, Kentucky Equality Federation President. "If Holsinger is confirmed it will alienate the gay community from the U. S. Public Health Service."

Kentucky Equality Federation will be sending its certified condemnation of Dr. James Holsinger as U. S. Surgeon General to U. S. Senator Ted Kennedy, the chairman of the U. S. Senate Committee on Health, Education, Labor, and Pensions.

"I think the committee needs to hear from Holsinger's home state," stated Palmer. "It is alarming that someone with a record such a Holsinger's, a record of allowing his personal religious opinion to influence his medical judgment, could be confirmed as our leading spokesperson on matters of public health in the U. S. government."

Kentucky Equality Federation will be asking its 6,841 registered members, as well as its 3,891 friends on the social networking website MySpace. com to sign a petition urging the Senate to reject Holsinger's nomination.

For additional information, visit http://www. commonwealth-equality. org (http://www. commonwealth-equality. org)

###

Rev. Michel Faulkner Seeks to Retire Charlie Rangel from New York's 15th Congressional Seat

Rev. Michel Faulkner Seeks to Retire Charlie Rangel from New York's 15th Congressional Seat

This November, voters in NY-15 can put an end to decades of unethical and disinterested leadership in Northern Manhattan by supporting Rev. Michel Faulkner, a former NFL player and community leader, for Congress.

New York, NY (PRWEB) March 11, 2010

After decades of serving the men and women of New York City through church leadership and nonprofit service, Rev. Michel Faulkner has announced that he wants to return democracy and ethical representation to the people of the Northern Manhattan. “The people of my community have been robbed of the American Dream because of unethical and ineffective leadership of Charlie Rangel and it is time for a change,” Rev. Faulkner said.

“I have always believed that my highest calling is to serve the powerless and speak for the voiceless,” explained Rev. Faulkner. “I will bring that same energy and drive as a representative of my community in Washington, D. C.”

As the Congressman representing New York’s 15th district, which includes Washington Heights, Harlem and parts of the Upper West Side, Rev. Faulkner will:
 Support small business initiatives to foster job creation  Support charter school expansion to improve education  Support community-based health and wellness initiatives  Reduce wasteful federal government spending and taxes

Rev. Faulkner’s experience and drive to serve make him the best person to represent the people of Northern Manhattan with honesty and integrity. Today, more than ever, the citizens of Harlem and Washington Heights need a trusted voice in Washington.

Rev. Faulkner will provide leadership with integrity, honesty and civility to the citizens of the 15th Congressional district, leadership which sets an example for the community, leadership which helps the community rise above the need for government dependency and bailouts, leadership which enables the citizens to realize their God-given potential.

About Michel Faulkner
Serving the city of New York for more than 20 years, Michel Faulkner got his start by playing in the NFL for the New York Jets in 1981 after graduating from Virginia Tech as an All-American. The next year, he returned to school to earn graduate degrees in education and career counseling.

Michel founded New Horizon Church of New York in Harlem in 2006. He previously served on Mayor Rudy Giuliani’s Task Force on Police Community Relations, and co-chaired the New York City Board of Education’s HIV/AIDS Task Force, was the Commissioner of the City Charter Review initiative and served as the Vice President for Community Government Relations at King’s College.

In addition to numerous radio and TV appearances, including Live with Regis and Kelly, Michel ran the Richmond Marathon in 2009 to raise money for the Run for Change Diabetes Awareness Campaign. He and his wife have been married for nearly 30 years and have three children.

About RaiseDigital

RaiseDigital (http://raisedigital. com (http://raisedigital. com)) is a new media consulting firm for non-profit and political entities. RaiseDigital is a leader in creating online brand awareness and establishing successful fundraising campaigns through various tools, including email and social networking.

For more information about Rev. Michel Faulkner, visit http://www. retirerangel. com (http://www. retirerangel. com).

# # #

Long-Term Experience With The DuraHeart™ Left-Ventricular Assist System Continues To Grow As Another Patient Surpasses Four Years Of Support On Device

Long-Term Experience With The DuraHeart™ Left-Ventricular Assist System Continues To Grow As Another Patient Surpasses Four Years Of Support On Device

Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today announced that another patient implanted with the DuraHeart™ Left Ventricular Assist System (LVAS) has surpassed four years after receiving the mechanical circulatory support device. Helga Gieseke, 66, who lives in the south of Saxony-Anhalt, Germany is now one of the longest-living heart failure recipients of this device designed to aid the pumping action of the heart in order to circulate blood throughout her body.

Ann Arbor, MI (PRWEB) August 11, 2010

Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today announced that another patient implanted with the DuraHeart™ Left Ventricular Assist System (LVAS) has surpassed four years after receiving the mechanical circulatory support device. Helga Gieseke, 66, who lives in the south of Saxony-Anhalt, Germany is now one of the longest-living heart failure recipients of this device designed to aid the pumping action of the heart in order to circulate blood throughout her body.

Mrs. Gieseke received the DuraHeart LVAS as an investigational device in May of 2006 after suffering from heart failure for many years. She was treated by the Physicians at The Deutsches Herzzentrum Berlin (DHZB, German Heart Institute Berlin) as part of the DuraHeart LVAS clinical study that ultimately lead to CE Mark and commercialization in Europe.

“I feel fortunate to have had the opportunity to continue doing many of the things I enjoy,” said Mrs. Gieseke. “I am thankful to all of the people involved in my care; it gives me the opportunity to spend more time with my family and see my grandchildren grow up. I’ve grown accustomed to having the device with me as it truly has become an important part of who I am; a patient living with chronic heart disease.”

Mrs. Gieseke has had a long history of heart problems; her first heart surgery was performed in 1994. Since then, Mrs. Gieseke had undergone several procedures including implantation of stents, pacemakers and implantable defibrillators in an attempt to manage her condition. Despite all these treatments, Mrs Gieseke’s condition continued to deteriorate until she found herself unable to walk or carry out simple activities around the house without getting chest pain. It was after admission to the local hospital in April of 2006 that Mrs. Gieseke was told by her cardiologist, also a school friend, that she required additional treatment. It was then that she was referred to The Deutsches Herzzentrum Berlin (DHZB, German Heart Institute Berlin).

“When Mrs. Gieseke was admitted in our Institution, she was in an advanced stage of chronic heart failure. Only an immediate heart transplant would have solved the problem, but a suitable donor heart was not available,” said Professor Roland Hetzer, Director of The Deutsches Herzzentrum Berlin (DHZB, German Heart Institute Berlin) stated. “Instead, we explained that she would need a mechanical heart assist device and proposed that she participate in the DuraHeart LVAS clinical trial. She has done extremely well living with the DuraHeart LVAS, which has proven to be quite durable and capable of providing the critical long-term support required by our heart failure patients.”

The DuraHeart LVAS can be used as a bridge to heart transplant in patients with end stage heart failure. Due to the scarcity of donor organs, patients can sometimes be on the waiting list for many months until a suitable donor becomes available. During that time, a patient’s condition can deteriorate dramatically until no other alternative is available to them. The left ventricular assist systems offer the patient a second chance while waiting for a suitable donor

“Mrs. Gieseke is yet another excellent example of the important work that leading Physicians around the world can accomplish in treating end stage heart failure, supported by the people at Terumo Heart,” said William Pinon, President and CEO, Terumo Heart. “It is truly gratifying to see the impact of our DuraHeart LVAS in bringing long-term quality of life back to patients who otherwise would have few options for treatment in the absence of a heart transplant.”

The DuraHeart LVAS is the latest-generation rotary blood pump designed for long-term patient support. The system incorporates a centrifugal flow rotary pump with the magnetically levitated impeller. The pump features three position sensors and electromagnetic coils that suspend the impeller inside the pump chamber without a single contact point. The impeller’s active magnetic levitation is designed to eliminate friction by allowing a wide gap between blood contacting surfaces, enabling blood to flow through the pump unimpeded in a smooth, non-turbulent fashion.

The DuraHeart LVAS is currently being studied in the DuraHeart Pivotal U. S. Trial for Bridge-to-Transplant (BTT), a multi-center, prospective, non-randomized study, involving 140 patients. The study, which was
Granted unconditional approval in early 2010 by the U. S Food & Drug Administration (FDA), will evaluate the safety and efficacy of the device in helping to sustain patients awaiting heart transplant who are at risk of death due to end-stage heart failure. The DuraHeart LVAS carries a CE Mark and is currently available for sale in European countries. The company has completed clinical trial enrollment for this device in Japan. Additionally, Terumo Heart has submitted its Destination Therapy Investigational Device Exemption to the FDA, which is a first step in the process of obtaining approval to begin its DuraHeart DT Clinical Trial in the U. S. 

For more detailed information about the DuraHeart BTT Trial, visit www. clinicaltrials. gov, and for more information about the DuraHeart LVAS, visit www. terumoheart. com.

About Heart Failure
More than 22 million people suffer from heart failure worldwide with approximately one million new patients diagnosed annually. In the setting of an aging global population, heart failure is the number one reason for hospitalization. The most severely ill patients need heart transplants in order to recover. More than 8,000 people worldwide are on the list of eligible candidates for heart transplants annually, but less than 3,000 receive a transplant each year. A large number of people who suffer from severe heart failure do not qualify for transplantation due to other health issues. An alternative for these patients is access to artificial mechanical assist.

About Terumo Heart, Inc.
Terumo Heart, Inc. is a U. S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company’s focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products. DuraHeart is limited to investigational use only in the United States, and is CE marked in Europe. For more information visit www. terumoheart. com

# # #

Six Tips for Environmentally Friendly Air Conditioner Storage

Six Tips for Environmentally Friendly Air Conditioner Storage

There are several important benefits to be gained from properly storing an air conditioner and implementing preventive maintenance. Not only will the air conditioner’s life be extended but owners will also see lower energy bills and they’ll be helping the environment by reducing CO2 emissions.

Austin, TX (PRWEB) October 21, 2006

Beating the heat during the dog days of summer can be an expensive business. While there is no real end in sight to rising energy costs, steps can be taken to ensure that related comfort expenses stay at a minimum for people and their families. Authorities agree that regular maintenance and proper storage of portable air conditioners will prolong their efficiency and life, reducing the frequency with which it will have to be replaced.

There are several important benefits to be gained from properly storing an air conditioner and implementing preventive maintenance. Not only will the conditioner's life be extended but energy bills will also see lower and you'll be helping the environment by reducing CO2 emissions. Combined, these six tips will help promote longevity, efficiency and family safety.

1. Store the AC unit well before the first frost. Trapped water could freeze and damage the air conditioner's internal components.

2. Remove and clean, or replace the air filter. If the filter is the permanent type, it can be washed with a mild detergent and reused.

3. Check the drain opening for blockage and drain any excess water in the portable air conditioner. Sometimes, mold or minerals build up and block the drain reducing the unit's effectiveness.

4. Check and clean the motor fan and compressor by blowing out the dust with an air hose. Check the compressor fittings for leaks using liquid soap or refrigerant leak detector.

5. Lubricate the fan and motor with standard off the shelf motor oil.

6. Store AC unit in a dry basement or attic, not on a garage floor, where it could come into contact with corrosive de-icing salts that can drip off of a car's tires. You can store the portable air conditioner in a closet or storage room – just make sure the prior steps are followed before doing so.

Two-thirds of all homes in the United States have air conditioners which use about 5% of all the electricity produced in the country - more than $11 billion dollars each year. In most cases, fossil fuels must be burned in order to produce electricity and when fossil fuels are burned, carbon dioxide is released into the atmosphere. Air conditioners release roughly 100 million tons of carbon dioxide into the atmosphere each year—an average of about two tons for each home with an air conditioner. This number can vary based on the health of an air conditioner. Units that are well maintained and stored properly will run more efficiently. This will ultimately lower electricity bills and CO2 emissions.

Shoppers can see reviews and other testimonials before purchasing their next AC. Air Conditioners America carries a wide selection of energy-saving portable room and window air conditioner units. They also make it easy for people to purchase air conditioners via their world-class e-commerce Web site. Their shopping consultants can help customers make the best decisions for their home and their needs. For easy to find products, detailed product information and a simple checkout process, visit: http://www. air-conditioners-america. com (http://www. air-conditioners-america. com)

###